The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors: JACC: CardioOncology State-of-the-Art Review
Abstract Sodium-glucose cotransporter-2 (SGLT2) inhibitors, originally approved for type 2
diabetes mellitus, have demonstrated efficacy in reducing cardiovascular events, particularly …
diabetes mellitus, have demonstrated efficacy in reducing cardiovascular events, particularly …
The cardioprotective potential of sodium-glucose cotransporter 2-inhibitors in breast cancer therapy-related cardiac dysfunction–A systematic review
Background Sodium–glucose cotransporter 2-inhibitors (SGLT2i) improve cardiovascular
outcomes including reduction in risk of first hospitalisation for heart failure (HF), worsening …
outcomes including reduction in risk of first hospitalisation for heart failure (HF), worsening …
[HTML][HTML] Double Duty: SGLT2 Inhibitors as Cardioprotective and Anticancer Allies
Sodium glucose cotransporter-2 inhibitors (SGLT2i), originally developed for type II diabetes
mellitus, have recently been approved for the treatment of heart failure in both diabetic and …
mellitus, have recently been approved for the treatment of heart failure in both diabetic and …